In vitro PK/PD modeling of tyrosine kinase inhibitors in non-small cell lung cancer cell lines
Clin Transl Sci. 2024 Mar;17(3):e13714. doi: 10.1111/cts.13714.ABSTRACTTyrosine kinase inhibitors (TKIs) are routinely prescribed for the treatment of non-small cell lung cancer (NSCLC). As with all medications, patients can experience adverse events due to TKIs. Unfortunately, the relationship between many TKIs and the occurrence of certain adverse events remains unclear. There are limited in vivo studies which focus on TKIs and their effects on different regulation pathways. Many in vitro studies, however, that investigate the effects of TKIs observe additional changes, such as changes in gene activations or protein expr...
Source: Clinical Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Linda Wanika Neil D Evans Martin Johnson Helen Tomkinson Michael J Chappell Source Type: research
Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes
Br J Clin Pharmacol. 2024 Mar 13. doi: 10.1111/bcp.16039. Online ahead of print.ABSTRACTWe sought to determine whether the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk of incident lung cancers among patients with type 2 diabetes. We assembled a new-user, active comparator cohort of SGLT-2 inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor users using the United Kingdom Clinical Practice Research Datalink. We fit Cox proportional hazards models with propensity score fine stratification weighting to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for incid...
Source: Clinical Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Samantha B Shapiro Hui Yin Oriana H Y Yu Laurent Azoulay Source Type: research
Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of < em > FLT3 < /em >
CONCLUSION: Although the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.PMID:38471061 | DOI:10.1200/JCO.23.02474 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 12, 2024 Category: Cancer & Oncology Authors: Mark J Levis Mehdi Hamadani Brent Logan Richard J Jones Anurag K Singh Mark Litzow John R Wingard Esperanza B Papadopoulos Alexander E Perl Robert J Soiffer Celalettin Ustun Masumi Ueda Oshima Geoffrey L Uy Edmund K Waller Sumithra Vasu Melhem Solh Asmita Source Type: research
Pulmonary coccidioidomycosis mimicking malignancy associated with Sweet's syndrome (acute febrile neutrophilic dermatosis)
Clin Case Rep. 2024 Mar 7;12(3):e8651. doi: 10.1002/ccr3.8651. eCollection 2024 Mar.ABSTRACTA suspicious malignant lung nodule with cutaneous reaction is not always cancer, especially in low risk for malignancy patients. A lung biopsy should be taken into consideration. The associated cause of Sweet's syndrome directs the treatment in each patient.PMID:38464569 | PMC:PMC10920303 | DOI:10.1002/ccr3.8651 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 11, 2024 Category: Cancer & Oncology Authors: Nattanicha Chaisrimaneepan Austin Guadarrama Pitchaporn Yingchoncharoen Maria Batchinsky Source Type: research
Parotid metastasis of rare lung adenocarcinoma: A case report
CONCLUSION: This case report highlights the challenging diagnosis of parotid metastasis in LC given its rare nature. Such lesions should be differentiated from primary tumors of the parotid gland. Simple radiological imaging is unreliable, and puncture biopsy is needed for final diagnosis of this condition.PMID:38464919 | PMC:PMC10921301 | DOI:10.12998/wjcc.v12.i6.1182 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 11, 2024 Category: Cancer & Oncology Authors: Ru-Xi Yan Lin-Bo Dou Zi-Jia Wang Xue Qiao Hong-Hai Ji Yan-Cong Zhang Source Type: research
